Gemcitabine/Irinotecan/celecoxib in pancreatic cancer.

Allan Lipton, Harold Harvey, Lois Witters, Samuel Kerr, Kathryn Legore, Cynthia Campbell

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Unresectable pancreatic cancer has few therapeutic options and a dismal prognosis. Cyclooxygenase-2 (COX-2) expression is increased at the RNA and protein levels in most human pancreatic cancers. The purpose of this trial was to determine whether the addition of a COX-2 inhibitor to chemotherapy was beneficial. To date, 11 patients with inoperable pancreatic cancer have been treated with the combination of gemcitabine (Gemzar), irinotecan (Camptosar), and celecoxib (Celebrex) at 400 mg orally twice daily. Encouraging pain relief, improvement in performance status, and decreases in CA 19-9 and carcinoembryonic antigen levels have been observed.

Original languageEnglish (US)
Pages (from-to)43-45
Number of pages3
JournalOncology (Williston Park, N.Y.)
Issue number14 Suppl 14
StatePublished - Dec 2004

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Gemcitabine/Irinotecan/celecoxib in pancreatic cancer.'. Together they form a unique fingerprint.

Cite this